When designing a trial you have the challenge of COST EFFECTIVELY establishing statistical significance. Companies with money to burn just do massively sized trials with looser inclusion criteria. RMTI, being on a budget, wisely designed a smaller trial where they planned for and culled the subjects for whom it would have been difficult to extract meaningful data and who would have dilluted the statistical data because of various factors. It was actually a smart thing to do.
The important thing to keep in mind is that the number of dropouts was generally similar on BOTH sides of the trial. The FDA will actually be happy to see this.
I'll let the uninformed short term sellers liquidate over the next couple of days and start buying more.
My goodness....do some background on how the trial was run. Then lets talk. Among others, if patients in the placebo dropped below a predefined safe Hgb level they were dropped because there was no way to normalize the Hgb levels without invalidating the trial design.. If patients in the SFP group showed higher than predefined Hgb levels because of " overly positive" responses to SFP, they too were dropped because again there was no way to normalize these levels without invalidating the trial. The data from these patients, however was included in the trial analyses and derived from the previous 2-3- weeks prior to drop out.